CDH17

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS

Retrieved on: 
Tuesday, October 31, 2023

FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy

Key Points: 
  • FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy
    Phase 1A clinical trial will enroll patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours
    SYDNEY, Oct. 31, 2023 /PRNewswire/ -- Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers.
  • The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • CHM 2101 is a 3rd generation, novel CDH17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.
  • With the FDA IND clearance Chimeric will now begin the initiation of a phase 1 /2 multi-site clinical trial in patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.

Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022

The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering.
  • There are more than 100 types of cadherins in humans, and many of them are not only responsible for cell adhesion but also involved in tumorigenesis.
  • CDH17 provides a great opportunity for drug discovery and development as the competitive landscape still is very favorable for new entrants, but the first molecules have entered clinical development.
  • The scientific rationale for CDH17-targeted therapies based on target characteristics and its differential expression profile;
    Preclinical proof-of-concept of CDH17-targeted different drug modalities;
    Clinical indications suitable for development of CDH17-targeted therapies and their patient populations;
    The competitive landscape of CDH17-targeted drug modalities in development;
    Specific profiles of CDH17-targeted drug modalities; and
    Profiles of companies active in the development of anti-CDH17 therapy candidates.

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies Bundle Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022

The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.
  • The tetraspan membrane protein is a member of the claudin family of tight junction proteins.
  • The transmembrane protein CLDN6 is virtually absent from any normal tissue, whereas it is aberrantly and frequently expressed in various cancers of high medical need.

Proactive news headlines including Hygrovest Ltd, Vango Mining, Australian Strategic Materials and Chimeric Therapeutics

Retrieved on: 
Thursday, June 9, 2022

Click here

Key Points: 
  • Click here
    Chimeric Therapeutics Ltd (ASX:CHM) has established a A$30 million equity funding agreement with leading global investor, L1 Capital Global Opportunities Master Fund.
  • Click here
    Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies

Retrieved on: 
Tuesday, April 12, 2022

MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, Chimeric) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered into a strategic manufacturing partnership with WuXi ATU, a global contract testing and manufacturing organization (CTDMO).

Key Points: 
  • MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, Chimeric) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered into a strategic manufacturing partnership with WuXi ATU, a global contract testing and manufacturing organization (CTDMO).
  • We are very excited to enter into this partnership with WuXi ATU, said Jennifer Chow, CEO of Chimeric Therapeutics.
  • Dr David Chang, CEO of WuXi Advanced Therapies, added, Were delighted to partner with Chimeric Therapeutics to accelerate the development of two of their autologous CAR T cell programs.
  • WuXi Advanced Therapies, a global Contract Testing Development and Manufacturing Organisation (CTDMO), is the advanced therapies business unit of WuXi AppTec and offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies for customers worldwide.

Proactive news headlines including Perpetual Resources, Northern Minerals, Orthocell Ltd and Australian Strategic Materials

Retrieved on: 
Tuesday, February 1, 2022

Click here

Key Points: 
  • Click here
    Australian Strategic Materials Ltd (ASX:ASM) ended the December quarter in a strong financial position, well-funded with A$56.9 million in cash as it advances its critical metal assets across Australia and South Korea.
  • Click here
    Archer Materials Ltd (ASX:AXE, OTC:ARRXF) says it has detected quantum information in its 12CQ chip for the first time on-chip, at room temperature, using mobile phone-compatible technology.
  • Click here
    ClearVue Technologies Ltd (ASX:CPV, OTCQB:CVUEF) has appointed industry veteran Basil Karampelas as its North American CEO.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006
    For more information on how Proactive can help you make a difference, email us at [email protected]

TRAIL Receptor 2 Agonists: Global Pipeline Insight, 2021 - Key Players are Inhibrx, Boehringer Ingelheim, IGM Biosciences, Amgen, Genmab, Theraly Fibrosis, and IGM Biosciences - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021

This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence TRAIL receptor 2 agonists R&D.
  • It also analyses TRAIL receptor 2 agonists therapeutic drugs key players involved in developing key drugs.
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TRAIL receptor 2 agonists therapeutics?

Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform

Retrieved on: 
Wednesday, December 1, 2021

Natural killer (NK) cells have innate safety features and the natural ability to target and destroy cancer cells through both indirect and direct mechanisms.

Key Points: 
  • Natural killer (NK) cells have innate safety features and the natural ability to target and destroy cancer cells through both indirect and direct mechanisms.
  • The challenge with natural killer (NK) cells is that they are not naturally abundant or active enough to overcome cancer.
  • Preclinical data on the CORE-NK platform was published in the prestigious family of Nature publications in 2019.
  • The phase 1 clinical trial of the CORE-NK platform was completed in June 2021 with clinical data expected in 2022.

Proactive news headlines including Core Lithium, Lotus Resources, Chalice Mining and SUDA Pharmaceuticals

Retrieved on: 
Friday, October 22, 2021

Click here

Key Points: 
  • Click here
    Lotus Resources Ltd (ASX:LOT) recently acquired the 6 million pound U3O8 Livingstonia Uranium Project located 90 kilometres from the companys Kayelekera Uranium Project in Malawi.
  • Click here
    SUDA Pharmaceuticals Ltd (ASX:SUD) has formally adopted the name Arovella Therapeutics Limited following an Extraordinary General Meeting on October 14, 2021, where shareholders voted to approve all resolutions.
  • Click here
    Twenty Seven Co Ltd (ASX:TSC) has completed its latest soil sampling program at the Rover Gold Project in WA.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006
    For more information on how Proactive can help you make a difference, email us at [email protected]